Astrazeneca Pharmaceuticals LP

Biopharmaceutical Company.

Based in DE

🤖

AI Overview

With $1.8M in lobbying spend across 27 quarterly filings, Astrazeneca Pharmaceuticals LP is a significant lobbying presence.

$1.8M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
1
Individual Lobbyists

Spending by Year

YearLobbying Spend
2018$200K
2019$150K
2020$120K
2021$240K
2022$240K
2023$320K
2024$240K
2025$320K

Lobbying Firms

W STRATEGIES, LLC

What They Lobby For

  • H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision and IPAB repeal. H.R.1625: Consolidated Appropriations Act, 2018.
  • H.R.1834: Cancer Care Payment Reform Act of 2017. Education about innovative contracting and value based payments. Synchronization and Nonadherence Correction (SYNC) Act. H.R.849/H.J.Res 51: IPAB Repeal Act and Joint Resolution related to IPAB Repeal.
  • Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule. CDC Recommendations about flu treatments.
  • H.R.1892: Bipartisan Budget Act of 2018 as it relates to a Part D donut hole provision.
  • Education about innovative contracting and value based payments. Education about the 340(b) drug discount program including the CMS 340(b) CMP Rule.
  • Education about innovative contracting and value based payments.
  • H.R.6642: "to sunset the limit on maximum rebate amount for single source drugs".
  • H.R.107: to sunset the limit on maximum rebate amount for single source drugs. Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act.
  • H.R.107: to sunset the limit on maximum rebate amount for single source drugs. H.R.3: Lower Drug Costs Now Act of 2019. Regulatory and legislative proposals in the Administrations Blueprint. H.R.2113: Prescription Drug STAR Act / H.R.2296: FAIR Drug Pricing Act. FY 2020 Continuing Resolution.
  • H.R.107: to sunset the limit on maximum rebate amount for single source drugs. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. Regulatory and legislative proposals in the Administrations Blueprint.

Related Investigations

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.